SV Health Managers

About SV Health Managers

SV Health Managers LLP is the UK-regulated manager entity behind the SV Health Investors brand, a transatlantic specialist healthcare and life-sciences investment platform. SV Health Managers is registered in England and authorised and regulated by the Financial Conduct Authority. The wider SV Health Investors firm was founded in 1993 (originally as SV Life Sciences) and was a pioneer of sector-dedicated healthcare venture capital. The firm operates from a dual-HQ structure across Boston, Massachusetts and London, United Kingdom, with a team of more than 50 investment professionals and operating partners. Assets under management crossed USD 4 billion (approximately €3.7 billion) following 2025 fundraising. SV currently manages dedicated vehicles across three core verticals: therapeutics funds (SV Life Sciences Funds III through VI, SV Biotech Crossover Opportunities Fund, SV7 Impact Medicine Fund, SV Fund IV Continuation Fund and the SV8 Biotech Fund LP), the growth fund (SV7-plus) and the Medtech Convergence Fund, alongside the dual-vintage Dementia Discovery Fund (DDF I and DDF II), the world's largest dementia-dedicated venture fund. Across more than three decades, SV has backed and built 200-plus companies.

Investment thesis

SV Health Investors pursues a specialist healthcare strategy investing across multiple stages and sectors, organised around three core verticals. Therapeutics funds early- to late-stage biotechnology companies developing precision medicines, often via SV-led company creation alongside seed seeding. Healthcare Growth (SV7-plus) provides growth capital and liquidity solutions to growth-stage healthcare services, medical products and digital-health companies. Medtech Convergence targets novel medical devices and remote-monitoring technologies. Ticket sizes vary by vertical: therapeutics deals typically deploy USD 10 to 50 million of equity per company across the lifecycle, growth-equity tickets typically run USD 25 to 75 million, and medtech tickets sit in the USD 5 to 30 million band. Geography is transatlantic across the US (Boston cluster, Bay Area, NYC) and the UK and Europe (Cambridge, Oxford, Continental hubs). The limited partner base spans pension funds, asset managers, family offices, charities, sovereign wealth funds and major pharmaceutical companies. The British Business Bank USD 100 million cornerstone commitment to SV8 Biotech in December 2025 is its single largest fund commitment ever, signalling deep UK strategic-state alignment. Value creation rests on company-formation expertise, a dense network of operating partners and life-sciences executives and active management of clinical-development and commercial milestones.

Recent activity

Recent investments include TRIMTECH in therapeutics and biotech (SV-created, 2024), a stealth-stage psychiatric and depression company (SV-created, 2024), Cerevance in therapeutics (2024) and QurAlis in therapeutics (2024). Recent exits include EyeBio in therapeutics and ophthalmology (2024 trade sale), Deciphera in therapeutics and oncology (2024 trade sale), BioAge Labs in therapeutics and longevity (2024 IPO Nasdaq), EBR Systems in medtech and cardiac (2024 IPO ASX) and a medtech portfolio name in medtech (2025 trade sale). The platform continues to deploy across therapeutics, healthcare growth and medtech convergence with the SV8 Biotech Fund providing fresh deployment capacity. Detailed buyer names and multiple data available on Pro at €29/month.